Banner - NPPA Connect
News|Videos|March 23, 2026

Previewing the Inaugural PANP360 Immersive Conference with Co-Chair Izabela Horzempa, PA-C

Key Takeaways

  • PANP360 prioritizes an immersive, single-day structure that balances efficiency with clinical depth for practicing dermatology advanced practice providers.
  • Interactive design integrates focused didactics, small-group discussions, and skills-based workshops to facilitate immediate translation into real-world dermatologic practice.
SHOW MORE

PANP360 Immersive will deliver one-day, high-yield dermatology CME for NPs and PAs, featuring hands-on workshops, complex case strategies, and practical tips to optimize therapies.

In this interview with Dermatology Times, Izabela Horzempa, PA-C, discussed the development and goals of the PANP360 Immersive Conference, a new CME initiative designed to address gaps in dermatology education for advanced practice providers. As co-chair, Horzempa emphasized that the conference was created to offer a concise, high-yield, one-day learning experience that balances efficiency with clinical depth—an approach tailored to the time constraints of practicing nurse practitioners (NPs) and physician assistants (PAs).

Unlike traditional multi-day meetings, the immersive format prioritizes practical learning and interactivity. Attendees can expect a blend of focused lectures, small-group discussions, and hands-on workshops, with an emphasis on real-world application. Key sessions include management of challenging conditions such as hidradenitis suppurativa, as well as care considerations for complex patient populations, including those who are pregnant or have comorbidities like inflammatory bowel disease or cardiovascular disease. Additional highlights include trichoscopy and updates on mechanisms of action for psoriasis therapies, reflecting the conference’s commitment to both foundational knowledge and emerging science.

Horzempa underscored that one of the distinguishing features of the meeting is its collaborative structure, fostering meaningful dialogue between faculty and attendees. The inclusion of the rapid-fire “15 Tips in 15 Minutes” session further reinforces the meeting’s practical focus, equipping NPs and PAs with actionable strategies that can be immediately implemented in practice.

A central clinical takeaway emphasized by Horzempa is the importance of optimizing existing therapies before escalating treatment. In an era of expanding biologic options for diseases such as psoriasis, atopic dermatitis, and prurigo nodularis, she encourages clinicians to carefully assess treatment duration, adherence, and potential barriers before transitioning patients to alternative agents. This approach supports more effective, evidence-based use of current therapies.

Beyond clinical education, Horzempa reflected on the professional growth associated with conference leadership, noting that involvement in program development provides insight into curriculum design and fosters collaboration with peers. She also highlighted the value of initiatives such as the Society of Dermatology Physician Assistants (SDPA) Emerging Scholar program in cultivating leadership skills and mentorship opportunities, which is where her leadership journey began.

To register and learn more about the PANP360 Immersive conference happening on April 18 in Philadelphia, Pennsylvania, click here.


Related to this article

Journal Digest: October 7, 2026
This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.
Day 3 Recap: Fall Clinical 2026
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Day 2 Recap: Fall Clinical 2026
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.